sar425899 dual agonist glp-1 glucagon sanofi Role of a Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor (Twincretin) in Glycemic Control: From Pathophysiology to Treatment Multiagonists Currently in Development. |

Another study exploring the effect of GLP-1 analogue on infarct size was done by Timmers L, et al

The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies

Beyond improving glycemic balance, semaglutide also reduces appetite, curbs food cravings, and supports better control over eating

FDA-approved options like semaglutide and tirzepatide have strong safety profiles, but a healthcare provider must determine which is most appropriate for your body

N Engl J Med 2022;387(9):852854

Early PsA may display nonspecific musculoskeletal symptoms, such as inflammatory arthralgia or morning stiffness, even in the absence of overt synovitis or radiographic erosions (12)